Code Compliance Committee
Interview with Chairperson Ouchi

The mission of the Code Compliance Committee is to manage, administer, and disseminate the JPMA Code of Practice (COP) and other voluntary standards to ensure that the actions of member companies comply with relevant laws and regulations. We believe that our activities to keep abreast of domestic and international regulations and industry trends in a timely manner and to promptly share necessary information will support the creation and maintenance of trust in the pharmaceutical industry, which in turn will directly lead to ensuring patient safety.

Especially since the establishment of the "Guidelines for Provision of Marketing Information on Ethical Drugs" in 2019, the form of information provision activities has changed significantly. In addition to the traditional face-to-face provision of information, webinars and online interviews are becoming more widespread, and the number of people responsible for providing information is expanding from MRs to MSLs and clinical development staff. In light of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Code, the JPMA has reorganized its framework to include all persons involved in promotion. We believe that the revised COP clarifies the point that the previous wording tended to be perceived as biased toward MRs. While the basic spirit remains the same, the clarification of the scope of the bearers is extremely significant.

At this point, the issue the committee considers is the degree of penetration of the COP. Even if the philosophy is shared, the degree of incorporation into actions differs from company to company, resulting in a situation in which the degree of compliance varies. It is important to fill in the gaps in understanding of COP through training and individual dialogue, showing specific examples.

Next, the impact of changes in promotion methods can be considered. Differences in devices themselves do not necessarily weaken promotion. However, new methods may cause unexpected oversights. In this regard, it is essential to work to increase the penetration of the revised COP.

Furthermore, the quality and compliance issues that have been pointed out in recent years are serious issues that affect the credibility of the industry as a whole. The Committee believes that the soundness of the industry is supported by the attitude of disclosing such incidents without concealment and promptly correcting them. We must enhance and maintain the credibility of the JPMA as a whole through preventive measures.

JPMA's Vision for 2035" states that the third pillar of the vision is to "ensure ethics and transparency and to become an industry trusted by society. As an organization that plays a central role in realizing this vision, the Committee has an urgent need to develop specific initiatives to foster and maintain public trust.

The most important task at hand is to ensure that the revised COP is well known to the public. The message must be conveyed according to the understanding of member companies and medical professionals who are the recipients of the message, not according to the perception of those who convey it.

In addition, training is conducted every year for member company code management managers and code practice managers. In October, we plan to hold a compliance-related kasuhara training for compliance managers and compliance practitioners. As for training, we interview member companies on a case-by-case basis regarding training deemed necessary.

In carrying out the activities of the Committee, it is necessary to continue to understand the actual status of the activities of pharmaceutical companies and identify issues. Through surveys of member companies, we will identify the factors that cause obstacles in the field and promptly provide necessary information and support.

Furthermore, as a contribution to "improving public literacy in health and medicine," as stated in "JPMA's Vision for 2035," we will strengthen external collaboration and international communication, actively participating in discussions with IFPMA and other organizations, reflecting Japanese findings from the IFPMA Code revision stage, and developing a "consensus framework for ethical collaboration in Japan. In addition, we are playing a central role in the "Consensus Framework for Ethical Collaboration in Japan". We will also strive to deepen dialogue and exchange views with the Japan Medical Association and other related organizations.

In committee operations, as the number of personnel with diverse backgrounds increases, it is essential to strengthen education and accompanying support to ensure that the Code of Conduct is equally disseminated to new members.

We believe that the most reliable and efficient risk management is the development of a "fire prevention system," which will lead to the reassurance of patients and the maintenance of public trust. Through these efforts, we will move forward toward a future in which the pharmaceutical industry is truly recognized as "an industry trusted by society.

The structure and activities of the Code Compliance Committee are posted on the JPMA website. Please visit the website.

Code Compliance Committee Website]
Code Compliance Committee | Information from the Committee | Japan Pharmaceutical Manufacturers Association